海正藥業(600267.SH):參與全國藥品集採 琥珀酸索利那新片擬中標
格隆匯1月17日丨海正藥業(600267.SH)公佈,2020年1月17日,公司參加了聯合採購辦公室(“聯採辦”)組織的第二批全國藥品集中採購的投標工作。公司根據《國家食品藥品監督管理總局關於發佈化學藥品註冊分類改革工作方案的公告》〔2016 年第51 號〕,按化學藥品新註冊分類批准的仿製藥品琥珀酸索利那新片擬中標本次集中採購,並且公司根據各省市場潛力進行了省份遴選。
擬中標產品基本情況如下:

公司於2019年7月獲得國家藥品監督管理局核准簽發的琥珀酸索利那新片的《藥品註冊批件》,截至目前該品種尚未實現銷售。經查詢IMS數據庫,琥珀酸索利那新片2018年和2019年1-9月在中國的銷售額分別為583.42萬美元、464.52萬美元。
此次藥品集中採購是國家組織在2020年1月開展的第二批國家藥品集中採購,在執行上要求全國醫療機構優先使用集中採購中選品種,並確保完成約定採購量。公司此次擬中選的品種為公司根據《國家食品藥品監督管理總局關於發佈化學藥品註冊分類改革工作方案的公告》〔2016 年第51 號〕,按化學藥品新註冊分類批准的仿製藥品,若確定中選、簽訂購銷合同並實施後,將有利於上述產品快速打開國內銷售市場,提高市場佔有率,促進公司製劑業務的進一步發展,提升公司的品牌影響力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.